Longevity Technology reports on Juvenescence investment in the important work of MDI Therapeutics.
Serine proteases have been described as the “workhorses of the human body.”
But serpins have historically been a challenging target for pharmaceutical development. MDI has shown that they can successfully use their proprietary high throughput screening platform to find novel drug candidates. Their lead program, a first-in-class orally available Plasminogen Activator Inhibitor (PAI-1) inhibitor, has demonstrated efficacy in multiple preclinical models of fibrosis and thrombosis, as well as a promising pharmacokinetic and safety profile. Juvenescence experience in bringing therapies to market, in addition to its equity investment, is seen as a strategic advantage for MDI.
Read the full Longevity Technology article here.
